Thymosin beta-4

Generic Name
Thymosin beta-4
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
77642-24-1
Unique Ingredient Identifier
549LM7U24W
Background

Thymosin Beta 4 has been investigated for the treatment of STEMI, Dry Eye, Diabetes, Pressure Ulcers, and Dry Eye Syndrome, among others.

Associated Conditions
-
Associated Therapies
-

Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients

First Posted Date
2018-02-28
Last Posted Date
2018-02-28
Lead Sponsor
Wen-hong Zhang
Target Recruit Count
240
Registration Number
NCT03448744
Locations
🇨🇳

Huashan Hospital of Fudan University, Shanghai, Shanghai, China

Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis

Phase 4
Completed
Conditions
Interventions
First Posted Date
2016-08-30
Last Posted Date
2019-04-04
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
20
Registration Number
NCT02883595
Locations
🇨🇳

Sun Yat-sen University, Guangzhou, Guangdong, China

The Efficacy and Safety of Ta1 for Sepsis

Phase 3
Completed
Conditions
Interventions
First Posted Date
2016-08-15
Last Posted Date
2023-04-10
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
1106
Registration Number
NCT02867267
Locations
🇨🇳

Shanghai Ruijin Hospital, Shanghai, Shanghai, China

🇨🇳

Guangzhou First People's Hospital, Guangzhou, Guangdong, China

🇨🇳

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

and more 19 locations

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

First Posted Date
2016-06-01
Last Posted Date
2016-11-25
Lead Sponsor
First People's Hospital of Hangzhou
Target Recruit Count
46
Registration Number
NCT02787447
Locations
🇨🇳

Hangzhou First People's Hospital, Hangzhou, Zhejiang, China

Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis

First Posted Date
2015-06-16
Last Posted Date
2021-04-05
Lead Sponsor
Weiqin Li
Target Recruit Count
508
Registration Number
NCT02473406
Locations
🇨🇳

Department of SICU, Research Institute of General Surgery Jinling Hospital, Nanjing, Jiangsu, China, Nanjing, Jiangsu, China

🇨🇳

Jinling Hospital, Nanjing, Jiangsu, China

Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye

Phase 2
Completed
Conditions
Interventions
First Posted Date
2011-07-04
Last Posted Date
2015-07-10
Lead Sponsor
ReGenTree, LLC
Target Recruit Count
72
Registration Number
NCT01387347

A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine

First Posted Date
2009-12-15
Last Posted Date
2012-03-29
Lead Sponsor
sigma-tau i.f.r. S.p.A.
Target Recruit Count
120
Registration Number
NCT01031966
Locations
🇮🇹

Second Division of Nephrology and Dialysis - Padua Hospital, Padua, Italy

Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers

Phase 2
Completed
Conditions
Interventions
First Posted Date
2009-01-29
Last Posted Date
2010-03-30
Lead Sponsor
RegeneRx Biopharmaceuticals, Inc.
Target Recruit Count
72
Registration Number
NCT00832091
Locations
🇮🇹

Università degli Studi di Napoli - Federico II, Naples, Italy

🇮🇹

Istituto Dermopatico dell'Immacolata (IDI), Rome, Italy

🇵🇱

Klinika Chirurgii Naczyń i Angiologii, Lublin, Poland

and more 5 locations

A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers

First Posted Date
2008-08-29
Last Posted Date
2017-04-17
Lead Sponsor
RegeneRx Biopharmaceuticals, Inc.
Registration Number
NCT00743769
Locations
🇺🇸

Healthcare Discoveries LLC, San Antonio, Texas, United States

Efficacy of Thymosin alpha1 for Severe Sepsis

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2008-07-09
Last Posted Date
2011-06-14
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
366
Registration Number
NCT00711620
Locations
🇨🇳

Sun Yat-sen University, Guangzhou, Guangdong, China

© Copyright 2024. All Rights Reserved by MedPath